Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 14:12:782457.
doi: 10.3389/fphar.2021.782457. eCollection 2021.

Mechanisms of the Rapid Effects of Ketamine on Depression and Sleep Disturbances: A Narrative Review

Bijia Song  1 , Jun-Chao Zhu  1
Affiliations
Review

Mechanisms of the Rapid Effects of Ketamine on Depression and Sleep Disturbances: A Narrative Review

Bijia Song et al. Front Pharmacol. .

Abstract

Recently, sleep has been recognized as a crucial factor for health and longevity. The daily sleep/wake cycle provides the basis of biorhythm, which controls whole-body homeostasis and homeodynamics. Sleep disturbances can contribute to several physical and psychological disorders, including cardiovascular disease, obesity, depression, and cognitive dysfunction. The clinical use of the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine began in the 1970s. Over the years, physicians have used it as a short-acting anesthetic, analgesic, and antidepressant; however, in-depth research has revealed new possible applications for ketamine, such as for treating sleep disturbances and circadian rhythm disorders. The aim of this narrative review is to examine the literature on the mechanistic role of the antidepressant ketamine in affecting sleep disturbance. Additionally, we discuss the pharmacologic and pharmacokinetic mechanisms of ketamine as an antidepressant and the predictive biomarkers for ketamine's effect on sleep and cognitive function.

Keywords: antidepressant; depression; ketamine; neurocognition; sleep disturbances.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Abdallah C. G., Sanacora G., Duman R. S., Krystal J. H. (2015). Ketamine and Rapid-Acting Antidepressants: a Window into a New Neurobiology for Mood Disorder Therapeutics. Annu. Rev. Med. 66, 509–523. 10.1146/annurev-med-053013-062946 - DOI - PMC - PubMed
    1. Ago Y., Tanabe W., Higuchi M., Tsukada S., Tanaka T., Yamaguchi T., et al. (2019). (R)-Ketamine Induces a Greater Increase in Prefrontal 5-HT Release Than (S)-Ketamine and Ketamine Metabolites via an AMPA Receptor-independent Mechanism. Int. J. Neuropsychopharmacol. 22 (10), 665–674. 10.1093/ijnp/pyz041 - DOI - PMC - PubMed
    1. Aleksandrova L. R., Phillips A. G., Wang Y. T. (2017). Antidepressant Effects of Ketamine and the Roles of AMPA Glutamate Receptors and Other Mechanisms beyond NMDA Receptor Antagonism. J. Psychiatry Neurosci. 42 (4), 222–229. 10.1503/jpn.160175 - DOI - PMC - PubMed
    1. Amr Y. M. (2010). Multi-day Low Dose Ketamine Infusion as Adjuvant to Oral Gabapentin in Spinal Cord Injury Related Chronic Pain: a Prospective, Randomized, Double Blind Trial. Pain Physician 13, 245–249. 10.36076/ppj.2010/13/245 - DOI - PubMed
    1. Barone P., Antonini A., Colosimo C., Marconi R., Morgante L., Avarello T. P., et al. (2009). The PRIAMO Study: A Multicenter Assessment of Nonmotor Symptoms and Their Impact on Quality of Life in Parkinson's Disease. Mov Disord. 24 (11), 1641–1649. 10.1002/mds.22643 - DOI - PubMed